June 13, 2017
June 13, 2017
Boonton, NJ – June 13, 2017 – Enteris BioPharma, Inc., Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, […]
March 30, 2017
March 30, 2017
Enteris BioPharma to Present at the 24th Annual Future Leaders in the Biotech Industry Conference Boonton, NJ – March 30, 2017 – Enteris BioPharma, Inc., a […]
January 30, 2017
January 30, 2017
Ferring Pharmaceuticals and Enteris BioPharma Enter License Agreement to Develop an Oral Formulation of a Peptide-based Injectable Therapeutic Saint-Prex, Switzerland and Boonton, NJ – January 30, […]
January 25, 2017
January 25, 2017
Enteris BioPharma Enters into Agreement with Nordic Bioscience’s KeyBioscience to Develop Orally Delivered Metabolic Peptide Enteris to lead the formulation and clinical manufacturing of Peptelligence®-enabled compounds […]
January 23, 2017
January 23, 2017
Enteris BioPharma Enters Agreement with Sanofi to Develop Investigational Oral Therapeutic for Type 2 Diabetes Feasibility Study to Examine Three Different Oral Formulations Engineered with Enteris’ […]
September 21, 2016
September 21, 2016
Enteris BioPharma’s “Feasibility to Licensing” Partner, Cara Therapeutics, Advances Peptelligence®-Engineered CR845 into Phase 2b Clinical Trial in Chronic Pain Trial to evaluate three tablet strengths of […]
July 13, 2016
July 13, 2016
Enteris BioPharma Initiates Clinical Program for Tobrate™ (oral tobramycin tablet) in Uncomplicated Urinary Tract Infection Tobrate adds to Enteris’ internal product pipeline and complements external, Peptelligence®-powered “feasibility-to-licensing” […]
KNOWLEDGE CENTER
Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.
LEARN MOREKNOWLEDGE CENTER
Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.
LEARN MORE
